Justin A. Newman

Justin A. Newman

Auto-generated profile, based on publicly available information

Justin A. Newman

Pharmaceutical Analysis & Digital Technologies, Merck & Company, Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2019 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DLDan Lehnherr
Dan Lehnherr
YLYu Hong Lam
Yu Hong Lam
MNMichael C. Nicastri
Michael C. Nicastri
JLJinchu Liu
Jinchu Liu
JNJustin A. Newman
Justin A. Newman
TRTomislav Rovis
Tomislav Rovis

24 March 2025 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HLHongming Li
Hongming Li
DTDavid A. Thaisrivongs
David A. Thaisrivongs
GSGao Shang
Gao Shang
YCYonggang Chen
Yonggang Chen
QCQinghao Chen
Qinghao Chen
JYJingjun Yin
Jingjun Yin

28 May 2024 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
NDNoah P. Dunham
Noah P. Dunham
MWMatthew S. Winston
Matthew S. Winston
RRRitwika Ray
Ritwika Ray
CEClaire M. Eberle
Claire M. Eberle
JNJustin A. Newman
Justin A. Newman
SSSteven M. Silverman
Steven M. Silverman

23 December 2022 in Green Chemistry
Verified
Journal Article
Closed access
PDF file
NKNadine Kuhl
Nadine Kuhl
BTBen W. H. Turnbull
Ben W. H. Turnbull
YJYining Ji
Yining Ji
RLReed T. Larson
Reed T. Larson
MSMichael Shevlin
Michael Shevlin
DTDavid A. Thaisrivongs
David A. Thaisrivongs
The development of a protecting group-free, 2-step synthesis of 5-amino-2-hydroxymethyltetrahydropyran 1a from biorenewable Cyrene™ is described which renders access to BTK-inhibitor nemtabrutinib (2) more efficient and sustainable.

16 May 2022 in Molecular Pharmaceutics
Verified
Journal Article
Open access
JNJustin A. Newman
Justin A. Newman
LILuca Iuzzolino
Luca Iuzzolino
MTMelissa Tan
Melissa Tan
POPeter Orth
Peter Orth
JBJessica Bruhn
Jessica Bruhn
ALAlfred Y. Lee
Alfred Y. Lee

10 April 2024 in ACS Materials Letters
Verified
Journal Article
Open access
AYAnna Yusov
Anna Yusov
ADAlexandra M. Dillon
Alexandra M. Dillon
MCMohammad T. Chaudhry
Mohammad T. Chaudhry
JNJustin A. Newman
Justin A. Newman
ALAlfred Y. Lee
Alfred Y. Lee
MWMichael D. Ward
Michael D. Ward
Single crystal X-ray diffraction (SCXRD) is arguably the most definitive method for molecular structure determination, but it is often challenged by compounds that are liquids or oils at room temperature or do not form crystals adequate for analysis. Our laboratory previously reported a simple, cost-effective, single-step crystallization method based on guanidinium organosulfonate (GS) hydrogen bonded frameworks for structure determination of a wide range of encapsulated guest molecules, including assignment of the absolute configuration of chiral centers. Herein, we expand on those results and report a head-to-head comparison of the GS method with adamantoid “molecular chaperones”, which have been reported to be useful hosts for structure determination. Inclusion compounds limited to only two GS hosts are characterized by low R1 values and Flack parameters, infrequent disorder of the host and guest, and manageable disorder when it does exist. The structures of some target molecules that were not included or resolved using the adamantoid chaperones were successfully included and resolved by the GS hosts, and vice versa. Of the 32 guests attempted by the GS method, 31 inclusion compounds afforded successful guest structure solutions, a 97% success rate. The GS hosts and adamantoid chaperones are complementary with respect to guest inclusion, arguing that both should be employed in the arsenal of methods for structure determination. Furthermore, the low cost of organosulfonate host components promises an accessible route to molecular structure determination for a wide range of users.